`Filed: November 16, 2015
`
`UNITED STATES PATENT AND TRADEMARK OFFICE ‘
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS, INC. and MYLAN
`PPLARMACEUTICALS, INC.,
`Petitioners,
`
`V.
`
`NOVARTIS AG and LTS LOHMANN THERAPIE—SYSTE1\/[E
`AG,
`Patent Owner.
`
`Case IPR2014—00549
`
`Patent No. 6,316,023
`
`I
`
`PETITIONER MYLAN’S MOTION TO
`
`WITHDRAW AS COUNSEL AND SUBSTITUTE NEW COUNSEL
`
`
`
`I.
`
`RELIEF REQUESTEE
`
`Pursuant to 37 C.F.R. § 42. l0(e), and as authorized by the Board via an
`
`email dated November 13, 20l5(see 37 C.F.R. § 42.20(b)), counsel for Co-
`
`Petitioner, Mylan Pharmaceuticals, Inc. (“Mylan”), respectfully requests
`
`authorization to withdraw as counsel for Mylan in this inter partes review
`
`proceeding.
`
`II.
`
`STATEMENT OF REASONS FOR SUBSTITUTION OF COUNSEL
`
`Mylan wishes for new counsel, Steven W. Parmelee (Reg. No. 31,990) and
`
`Michael T. Rosato (Reg. No. 52,182) to be designated as lead and bacl<—up counsel,
`
`respectively, and represent Mylan going forward in this proceeding. Petitioner’s
`
`new counsel meet the requirements of the 37 C.F.R. § 42.l0(c) as registered
`
`practitioners.
`
`No extension of time will be needed upon grant of this Motion, the Final
`
`Written Decision having been issued September 28, 2015. It is believed that
`
`granting this Motion will not hinder the economy, the integrity of the patent
`
`system, the efficient administration of the Office, or the ability of the Office to
`
`timely complete this proceeding. See 35 U._S.C. § 3 l6(b). Patent Owner and Co-
`
`Petitioner, Noven Pharmaceuticals, Inc. have indicated in emails dated November
`
`13, 2015 that they do not oppose this Motion.
`
`An executed updated Power of Attorney and updated Mandatory Notices
`
`under 37 C.F.R. § 42.8(b)(3) are being filed concurrently.
`
`
`
`Date:
`
`/M)‘/‘ /6; Z867
`I
`
`Respectfully submitted,
`
`’
`"% MK
`"seph M. Reisman, Lead Counsel
`Reg. No. 43,878
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that the foregoing Petitioner’s Motion to Withdraw as Counsel and
`
`Substitute New Counsel was served on this 16”‘ day of November, 2015, on Co-
`
`Petitioner Noven Pharmaceuticals, Inc., and the Patent Owner at the
`
`correspondence addresses as follows:
`
`CO-PETITIONER NOVEN PHARMACEUTICALS, INC.:
`
`Steven J. Lee
`
`Michael K. Levy
`Christopher Coulson
`KENYON & KENTON LLP
`
`slee
`
`ken on.com
`
`mlevy@,kenyon.com
`ccoulson[@kenyon.com
`
`PATENT O WNER:
`
`Raymond R. Mandra, Esquire
`Nicholas N. Kallas, Esquire
`Charlotte Jacobsen, Esquire
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`
`New York, New York 10104-3800
`ExelonPatchIPR@fchs.com
`
`Respectfully submitted,
`
`Date:
`
`
`
`/WI/» /6 ZOCK %/f
`
`oseph M. Reisman, Lead Counsel
`Reg. No. 43,878